Choline Chloride

PreclinicalSmall molecule

NNorthwestern University

Choline Chloride is one of 43 small molecule programs targeting Cystic Fibrosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cystic FibrosisActive, not recruiting

Parenteral NutritionCompleted

Cystic FibrosisPreclinical

Active, not recruiting

Parenteral NutritionPreclinical

Completed

Competition

Competitive Landscape

107 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Ibsrela

AArdelyx

Phase 3

1 2

Lamprene

Novartis

Phase 2

1 3

HSK31858

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

2 4

Myambutol

VVA Greater Los Angeles Healthcare System

Phase 2

2 5

Sirturo

WWim Janssens

Phase 2

1 6

ELX/TEZ/IVA

Vertex Pharmaceuticals

Phase 3

18 7

Trikafta

NNottingham University Hospitals NHS Trust

Phase 3

4 8

VNZ/TEZ/D-IVA

Vertex Pharmaceuticals

Phase 3

1 9

VX-121/TEZ/D-IVA

Vertex Pharmaceuticals

Phase 3

4 10

Verapamil Hydrochloride

Mylan Pharmaceuticals Inc

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cystic Fibrosis1 trial

Examination of the Lipid Metabolism of the Liver After Choline Substitution in Cystic Fibrosis

Completed·UUniversity Hospital Tuebingen·N/A·NCT03312140·10 enrolled

Parenteral Nutrition1 trial

Randomized Study of the Use of Intravenous Choline Supplementation in Long Term Total Parenteral Nutrition

Completed·UUniversity of Texas·N/A·NCT00004697·15 enrolled

Liver Disease1 trial

Total Parenteral Nutrition-Associated Liver Disease

Terminated·NNorthwestern University·Phase 2·NCT00031135·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Choline Chloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Choline Chloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Choline Chloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Northwestern University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNorthwestern University

Choline Chloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cystic Fibrosis1 trial

Parenteral Nutrition1 trial

Liver Disease1 trial

References

Drug Info

Quick Facts

Related News